Navigation Links
Commercial Medical and Pharmacy Benefit Enrollment Down in New York

HealthLeaders-InterStudy's Managed Market Surveyor-Rx Evaluates How Medical and Pharmacy Lives are Covered at National, State and MSA Levels

NASHVILLE, Tenn., June 17 /PRNewswire/ -- HealthLeaders-InterStudy, the leading provider of managed care market intelligence, reports that medical and pharmacy benefit enrollment in New York state declined between July 2008 and January 2009. According to data available in the newest release of Managed Market Surveyor-Rx, medical benefit enrollment declined 2.7 percent throughout the state (approximately 340,000 lives), while pharmacy benefit enrollment declined 3.6 percent (approximately 335,000 lives).

"The economy plays a large role in the enrollment declines seen in New York, particularly as the number of unemployed in the state nearly doubled in 2008," said Rebecca Waller, senior health plan analyst with HealthLeaders-InterStudy. "Overall, enrollment has decreased in New York at a higher rate than most other states."

In some states, insurers are able to retain some business lost through layoffs and business closures with sales to the individual market, but that sector is less of a factor in New York. State rules regarding medical underwriting make prices for individual designs relatively high.

The shifts seen in the New York market are just one example of the data available in Managed Market Surveyor-Rx.

"Managed Market Surveyor-Rx allows users to identify managed care enrollment trends across plans, plan type and geography to better inform resource deployment," said Russell Workman, principal director of data operations for HealthLeaders-InterStudy. "For pharmaceutical companies contracting with plans operating in New York, and throughout the country, our database provides a comprehensive assessment of a plan's market share by metropolitan statistical area (MSA) and its capacity in that market."

Why Pharmaceutical Companies Need Managed Market Surveyor-Rx

Managed Market Surveyor-Rx delivers medical and pharmacy benefit enrollment data by managed care organization and geography (national, state, MSA) to better inform strategic planning and resource allocation. Relying on primary research and HealthLeaders-InterStudy's proprietary validation methodology, Managed Market Surveyor-Rx provides the most accurate managed care database available.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE HealthLeaders-InterStudy
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AMDL CEO Featured in CEOCFO Magazine; Details Progress on DR-70 International Commercialization Strategy & Confidence in FY2009 Financial Forecast
2. Study Shows Increases in Working After 65 and Using Commercial Insurance
3. Commercial Pharmacy Benefit Enrollment Experiencing Greater Shifts in Florida than Commercial Medical Benefit Enrollment
4. Endologix Announces Full Commercial Launch of IntuiTrak Express Delivery System
5. China Sky One Medical, Inc. Welcomes Commercial Counselor from Belgium; Looks for Business Alliance with European Companies
6. ProSolv Version 4.0.2 Makes Commercial Debut at ASE
7. moksha8 Expands Alliance With Roche to Commercialize $200 Million of Products in Brazil and Mexico
8. Apieron Strengthens Senior Leadership With Commercial, Financial Appointments
9. BD and HandyLab Announce Exclusive Collaboration to Commercialize Molecular Assays
10. AMDL, Inc. Enters Into Distribution Agreements With GenWay Biotech, Inc. to Advance Commercialization of the DR-70 (FDP) Cancer Test in the US and Canada
11. Cardium Reports on New Excellarate(TM) Product Formulations to Expand Commercialization Potential Into Multiple Wound Healing Applications
Post Your Comments:
(Date:11/29/2015)... ... November 29, 2015 , ... ... unique analog distortion effect tool designed specially for Final Cut Pro X. ... limiltess looks with the easy-to-use modification controls. Destoying and creating chaotic distortion is ...
(Date:11/28/2015)... ... , ... Trying to relax on a couch can actually be uncomfortable, so ... design due to personal experience with a bad back," he said. , This easy-to-use, ... well as increases support. It also makes it easier to eat, do other activities ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... the University of Toronto and the University of British Columbia suggested that laws requiring ... injuries. The article explains that part of the reason for the controversial conclusion is ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
Breaking Medicine Technology: